AstraZeneca-Forest's superbug antibiotic positive in Phase III
This article was originally published in Scrip
Executive Summary
AstraZeneca has reported positive top-line results from RECLAIM-1 and RECLAIM-2, the pivotal Phase III studies investigating the antibiotic ceftazidime-avibactam (CAZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections.